Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Monday that it has reported positive results from the Phase III ANCHOR trials for depemokimab, a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). Both ANCHOR-1 and ANCHOR-2 trials met primary endpoints, demonstrating a statistically significant reduction in nasal polyp size and nasal obstruction after 52 weeks compared to placebo and standard care.

Depemokimab, an ultra-long-acting biologic administered biannually, targets interleukin-5 (IL-5), a key driver of type 2 inflammation present at high levels in nasal polyp tissue. The drug aims to provide sustained suppression of inflammation, potentially benefiting patients by minimizing treatment interruptions and reducing clinic visits.

CRSwNP affects up to 4% of the population, with around 40% of cases remaining uncontrolled. Symptoms, including nasal obstruction and loss of smell, can significantly impact quality of life. Many patients exhibit type 2 airway inflammation, which correlates with more severe disease and higher rates of surgical interventions.

Data from these trials will be included in global regulatory submissions, as GSK seeks to advance treatment options for type 2 inflammatory conditions. Depemokimab is not yet approved for any indication.

The ANCHOR trials were randomized, double-blind studies involving 143 participants in ANCHOR-1 and 129 in ANCHOR-2, comparing depemokimab against placebo over 52 weeks. GSK's development programme for depemokimab also includes evaluations in severe asthma and other IL-5 mediated diseases.

GSK continues to innovate in respiratory medicine, focusing on improving outcomes for patients with asthma and chronic obstructive pulmonary disease, leveraging cutting-edge science and technology.